

# The Next Generation of Precision Cancer Treatment

Revolutionizing oncology through advanced molecular analytics and  
customized multi-modal therapy for the global elite.

---

PRESENTED BY JSCSF | JAPAN SOCIETY OF CLINICAL FRONTIER

# | Beyond Staging: The New Paradigm

## Why Standard Treatments Plateau

Traditional "Staging" is a surgical metric, not a biological one. It fails to account for cell type and dynamic concentration.

### Standard Care Survival

Stage IV 5-Year Survival: **~10%**

Focuses only on "Cutting" (Surgery) or "Bombarding" (Systemic Chemo).

## The JSCSF Advantage

By focusing on "Type & Concentration," we achieve outcomes previously thought impossible in advanced cases.

### JSCSF S-Style Survival

Stage IV 3-Year Survival: **83.3%**


Integrated precision medicine targeting the root biological cause.

# CTC Analysis: Targeted Intelligence

Using cutting-edge **Microfluidic Chip Technology**, we isolate Circulating Tumor Cells (CTCs) to identify their specific phenotype.

- ✓ **Epithelial (Type 1):** Vulnerable to standard chemotherapy.
- ✓ **Mesenchymal (Type 2):** The "Queen Bee" – resistant to chemo and responsible for metastasis.
- ✓ **Intermediate (Type 3):** Cells in transition, highly aggressive.

Detecting even one cell enables us to predict recurrence years before imaging (PET-CT/MRI).



# | cfDNA: The Molecular Velocity Gauge



cfDNA concentration  $(pg/\mu l)$  is the ultimate metric for measuring "Cancer Velocity." Our goal is to drive this value below 700 through targeted therapy

# | Immune Profiling: Preventing "Turbo Cancer"



## S-Protein IgG4

Advanced screening for mRNA spike-protein specific IgG4 antibodies, which can suppress the body's natural anti-tumor immunity.



## Turbo Cancer Risk

Identifying high-risk immune profiles where cancer can progress from Stage 1 to Stage 4 in mere months.





## Immune Restoration

Targeted removal of immunosuppressive factors to reactivate the body's native NK and NKT cell defenses.

# Advanced Multi-Modal Therapy

Our proprietary "**S-Style Treatment**" integrates global medical breakthroughs:

-  **Iodine Therapy:** Halting EMT (Metastasis) via PPAR $\gamma$ .
-  **PAPLAL:** Platinum-Palladium reactive oxygen scavenging.
-  **Germanium:** Enhancing oxygen transport and analgesia.
-  **Met-Enzyme:** Stopping cell division at the G2 phase.



# Investment in Longevity: Fee Schedule

Comprehensive treatment plans are customized based on biological urgency (cfDNA levels).

Diagnostic Indicator	Biological Stage	Treatment Investment (Base)
cfDNA < 1,000 pg/μl	Stage 0 / Ultra-Early	¥ 1,500,000 (Excl. Tax)~
cfDNA < 1,500 pg/μl	Stage 1	¥ 2,500,000 (Excl. Tax)~
cfDNA < 2,000 pg/μl	Stage 2	¥ 4,500,000 (Excl. Tax)~
cfDNA < 2,500 pg/μl	Stage 3	¥ 6,500,000 (Excl. Tax)~
cfDNA < 3,000 pg/μl	Stage 4	¥ 8,500,000 (Excl. Tax)~
cfDNA ≥ 3,000 pg/μl	Advanced / Critical	Private Consultation Required

# Exclusive Consultation

Secure your future with the world's most advanced cancer screening and integrated medical solutions.



Japan Society of Clinical Study For Frontier Medicine (JSCSF)

**Private Concierge for International VIPs**

Tokyo | Osaka | Fukuoka